Jeffrey C Goh

4PUBLICATIONS
53CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Sep 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer, Axel Bex, Paul Russo

|Jan 16, 2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.

Robert J Motzer, Camillo Porta, Masatoshi Eto

|Jun 08, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh

|Aug 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.

Amit M Oza, Domenica Lorusso, Carol Aghajanian

Pageof 1

Frequent Collaborators

2 joint publications

Viktor Grünwald

2 joint publications

Robert J Motzer

1 joint publications

Amit M Oza

1 joint publications

Ana Oaknin